X

Trial Profile

A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 Jan 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Zilovertamab (Primary)
Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms CIRLL
Sponsors Oncternal Therapeutics, Inc.

Most Recent Events

13 Dec 2022 Results (n=95), presented at the 64th American Society of Hematology Annual Meeting and Exposition
10 Dec 2022 According to an Oncternal Therapeutics media release, interim results presented at the American Society of Hematology (ASH) 2022 Annual Meeting.
10 Dec 2022 Interim results (n=33) presented in an Oncternal Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com